We have joined forces with 19 other less common cancer charities to create a unique & exciting 20-day challenge called the 20for20 Challenge to raise funds to make up the shortfall in our income due to the pandemic. Funds that are vital to enable us to continue with our work. The Covid-19 pandemic has led […]

We are delighted to hear that our friends at the Scottish Sarcoma Network (SSN) have been shortlisted for the BMJ 2020, “Cancer Care Team of the Year award” for their “National Sarcoma MDT improvement project”. This project which was initiated by Dr Ioanna Nixon and co-led by Dr Mark McCleery and Lindsay Campbell on behalf […]

In 2017 GIST Cancer UK approved a research grant application for pathologist Dr Newton Wong to undertake next generation sequencing  (NGS) of wild-type GIST’s to identify therapeutic targets. Earlier this month (July 2020) – Dr Wong’s research paper “Next generation sequencing demonstrates the rarity of short kinase variants specific to quadruple wild type gastrointestinal stromal […]

GIST Cancer UK is excited to announce that we have appointed three new trustees. The charity is made up of a board of volunteer trustees, many of whom are GIST patients or carers. The New trustees, Tony Manuel, Jane Means and Terry Riley bring a range of crucial skills and experience to help the charity […]

13th July is GIST Awareness Day! Please help us to reach everyone whose lives are touched by GIST Cancer so they can benefit from the help and support that our GIST Cancer UK community offers. Please click this link Raising awareness and being aware – here are some more inspiring stories: Jo’s Story  Pippa’s Story  […]

This weekend the Liferaft group of America are hosting their “LifeFest meeting” as a virtual event for GIST Patients and their families. The programme includes talks from GIST researchers and specialists which you may find interesting. There is also a special session on Monday 13th July for SDH deficient GIST patients where the panel of […]

We are very pleased to hear that NICE has approved the Roche drug Entrectinib (Rozlytrek), for use via the Cancer drug fund (CDF) in England by adults and children 12 years and older, who have advanced NTRK (Neurotrophic Tyrosine Receptor Kinase) fusion-positive solid tumours and no satisfactory treatment options. Eligible patients will have access to […]

This week Blueprint Pharmaceuticals announced the results of their Voyager trial which compared AYVAKIT™ (avapritinib) with Regorafenib. The trial did not meet the main aim (or endpoint). As a result they are proposing: To continue promoting avapritinib in the United States for the treatment of adults with unresectable or metastatic PDGFRA exon 18 mutated GIST, including […]

On Sunday 26 April the London Marathon was cancelled due to the coronavirus outbreak and it is likely that many other events that would normally involve our fantastic #GISTCANCERUK & #PAWSGIST supporters will also not go ahead this year. So, we are hoping that you can have some fun while in lock down and raise vital […]

We are very pleased to announce that NICE has approved the Bayer drug Larotrectinib (Vitrakvi) for use via the Cancer drug fund (CDF) in England for adults and children who have failed other treatment options and whose tumours test positively for the rare NTRK fusion (Neurotrophic Tyrosine Receptor Kinase fusion). Described as an histology agnostic […]